LONDON, Feb. 23, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of United States patent 7,893,245, titled "Interfering RNA Molecules," by the United States Patent and Trademark Office (USPTO). The issued patent, which represents a continuation of previously issued U.S. Patent Number 7,452,987, covers chemically modified RNAi molecules with defined positional modifications including siRNA molecules that are blunt ended, as well as molecules with one or more overhangs. Importantly, this latest patent broadens Silence's protection of these RNAi molecules to those with a chemically modified core length between 17 and 29 nucleotides including the company's portfolio of 25mer siRNA sequences. This patented siRNA technology forms the foundation for AtuRNAi, Silence's propriety RNAi molecules. Various therapeutics incorporating Silence's AtuRNAi technology are currently being studied in five ongoing clinical trials conducted by Silence Therapeutics and other industry leaders.
"The extended protection for our RNAi technology, particularly the expanded coverage of our AtuRNAi platform, reinforces the meaningful advances Silence Therapeutics is making in the field of RNAi therapeutics. The AtuRNAi technology is actively being advanced in multiple Phase II clinical studies by Quark and in our own Phase I trial and to date more than 200 patients have been dosed with AtuRNAi with no reported safety issues," stated Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics. "The value of the AtuRNAi technology is an essential component of all of our internal and partnered programs. With the extended protection for the AtuRNAi technology, which can be combined with our broadly protected structural modification technology (the 'Zamore Design Rules,'), we and our partners are able to invest in product development more aggressively."
In related intellec